Press Releases BioLineRx Ltd.

Equities

BLRX

IL0011015182

Market Closed - TEL AVIV STOCK EXCHANGE Other stock markets 10:31:09 2024-05-02 am EDT			5-day change	1st Jan Change
15.1 ^ILa	-15.64%		-10.12%	-60.47%

Apr. 17	BioLineRx Ltd. Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists Including APHEXDA® (Motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting	CI
Apr. 10	BioLineRx Ltd. Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioLineRx : Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting	Apr. 17	PU
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement	Apr. 10	PR
BioLineRx Announces $6 Million Registered Direct Offering	Apr. 02	AQ
BioLineRx : Form 20-F/A (Amendment No. 1	Mar. 28	PU
BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates	Mar. 27	AQ
BioLineRx : Annual Report on Form 20-F FOR 2023	Mar. 26	PU
BioLineRx : Report of Periodic or Interim Report	Mar. 26	PU
BioLineRx : Reports 2023 Financial Results and Recent Corporate and Portfolio Updates	Mar. 26	PU
BioLineRx to Report 2023 Annual Financial Results on March 26, 2024	Mar. 20	PR
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production	Mar. 04	PR
BioLineRx : FORM F-3-REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933	Dec. 31	PU
BioLineRx : FORM S-8-registration of Ordinary Shares to be issued under the Plan	Dec. 31	PU
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease	Dec. 21	PR
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates	Nov. 21	AQ
BioLineRx to Report Third Quarter 2023 Results on November 20, 2023	Nov. 13	PR
BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Ventures	23-10-31	PR
BioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer	23-09-29	AQ
BioLineRx Announces Acceptance of Oral Presentation on Pilot Phase Data from Phase 2 Combination Clinical Trial with Motixafortide in First-Line PDAC at AACR Special Conference on Pancreatic Cancer	23-09-20	AQ
BioLineRx Announces FDA Approval of APHEXDA in Combination with Filgrastim to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma	23-09-12	AQ
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates	23-08-31	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases BioLineRx Ltd.

Equities

BLRX

IL0011015182

Press Releases

Filters